Next Phase Newsletter

A corporate venture capital arm of a global company invests to further the parent company’s future strategic position, rather than purely for financial returns.  The firm looks to make equity investments into emerging biotech companies with typical investments ranging from $1 million to $6 million, with additional capital reserved for follow on investments. The firm has no set allocations it plans to make over the next year but is actively reviewing new opportunities. The firm considers opportunities located around the globe.

The firm is looking for biopharmaceutical companies developing therapeutics and therapeutic platforms generally at the preclinical stage and is open to considering both small molecules, biologics, nucleic acid, and gene and cellular therapeutic approaches. The firm is interested in various indications including immunology and autoimmune diseases (rheumatology, dermatology and gastroenterology), neuroscience (only neurodegenerative diseases) and oncology. The firm is not investing in diagnostics, devices or healthcare IT.

The firm is looking for companies with experienced management teams with domain expertise. The firm strongly prefers board representation following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Founded in 2016, the firm has offices in USA and China. The firm has two RMB funds and one USD fund: The two RMB funds focus on the local Chinese market; while the USD fund invests in Hong Kong and non-China market. The firm’s USD Fund has invested in 7 companies, half of which are in the novel drugs area, and will continue to invest in Seed to pre-Series A. The typical allocation size will be $0.5MM to $1 MM, and up to $3.5 MM.

The firm is mainly interested in the Therapeutics innovations including orphan drugs, that are in pre-clinical to Phase II stage, especially CAR-T, small molecules and CRISPR. The firm is also open to medical devices companies, which are in development or clinical stage, but holds a strict valuation on diagnostics companies. The firm is not interested in Healthcare IT.

The firm has no specific company & management Team Requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A holding company based in South Korea is actively seeking global early-stage investment opportunities in bio/healthcare sectors, and actively invest in biotech VC funds as well. Initial size of investment largely depends on a deal-by-deal basis.

With regards to life sciences, the firm is most interested in therapeutics or diagnostics companies with a particular interest in platform technologies. The firm is most interested in CNS, oncology, and immuno-oncology opportunities. While the firm is open to investing in medical devices or digital health, these are not a priority for the firm.

The firm does not have specific company or management team requirements. The firm does not require companies to have a Korea angle or market potential in Korea, but the firm can provide strategic value add if the companies were interested in Asia market expansion.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family investment group based in the USA is looking to invest in technologies related to ophthalmology and oncology that are in the pre-clinical to Ph I stages. The firm will invest in seed and series A rounds up to $10M. The firm is willing to invest globally, with a special interest in companies based in North America, Europe and China.

The firm is interested in therapeutics, medical device and diagnostics companies with technologies in the ophthalmology and oncology spaces. The firm may consider digital health companies as well. For ophthalmology-related companies, Halcyon is most interested in small molecules or combination devices. For oncology-related companies, the firm prefers I/O technologies or diagnostics.

The firm prefers to take a board seat after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm with offices in the USA is actively investing in early-stage life science companies, primarily from Series A to beyond. Typical investment size ranges between $5-20M USD, and the firm works together with its network of other active investment firms and family offices to form investment syndicates. The firm is focused on companies based in USA and Canada, but is open to evaluating highly promising companies beyond North America.

The firm invests in therapeutics and devices, and digital health to a much lesser extent. The firm will not consider wearables. With regards to therapeutics, the firm is most interested in clinical stage companies (pre-clinical will most likely be considered too early stage) in the anti-infective space. The firm does look at other modalities and indications given that they are fairly advanced clinical assets. In terms of medical devices, the firm will consider those that are very close to, or already gained FDA approval. The firm is agnostic in terms of subsectors and indications, but is most interested in technologies that address a large market and can be applied in a wide scale. The firm has reviewed technologies in ophthalmology, cardiovascular, and pulmonary indications with positive interest.

The firm has no specific company or management team requirements, though strong intellectual property is considered a huge plus. The firm generally acts as a co-investor, but also engages fellow investors in their network to syndicate investment rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm headquartered in China with an additional office in USA, is currently managing a venture capital fund in RMB with a total of 500 MM RMB (~70MM USD). The firm is currently focusing on the early-stage (from angel to series B) investments, with initial investment ranging from 3MM RMB (400,000 USD) to 5MM RMB (700,000 USD). The management team supports the firm with decades of experience in both the U.S. and China and is open to investing globally.

The firm has a general interest in the early-stage life science technology assets, especially therapeutics and medical devices. The fund also opens to diagnostics and healthcare IT, with the proven record of investing in hospital AI service platforms.

The firm prefers companies with China Angle, especially companies who are willing to register an entity/branch/joint venture in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Western Europe owns several funds and currently focuses on investments in Europe based diagnostics companies. The firm invests in Europe and North America, and typically allocates about €5 million equity to each portfolio company, generally over several tranches.

The firm invests in therapeutics and diagnostics to treat rare diseases.  The firm is agnostic regarding technologies and indication areas, and typically invests early but is open to companies with assets ranging from preclinical development through Phase II.

The firm prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.